Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. is a clinical-stage precision therapeutics biotechnology company focused on discovering and developing medicines that treat serious diseases by correcting abnormal gene expression through selective targeting of the chromatin regulatory system. The company's website is www.foghornrx.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Foghorn Therapeutics Inc. does
In the company’s own words
Foghorn Therapeutics Inc. is a clinical-stage precision therapeutics biotechnology company focused on discovering and developing medicines that treat serious diseases by correcting abnormal gene expression through selective targeting of the chromatin regulatory system. The company's website is www.foghornrx.com.
The company operates a proprietary Gene Traffic Control platform that provides integrated mechanistic understanding of how various components of the chromatin regulatory system interact, enabling identification, validation, and drugging of targets within this system. Foghorn believes it is the only company with the ability to study and target the chromatin regulatory system at scale, in context, and in an integrated way. The chromatin regulatory system is implicated in approximately fifty percent of all cancers and has potential applications across immunology, inflammation, virology, autoimmune disease, and neurology.
Foghorn's current pipeline includes more than seven programs with one clinical-stage drug candidate in Phase 1 development. The company has discovered highly selective chemical matter for challenging oncology targets including SMARCA2, CBP, EP300, and ARID1B. The company's lead program, FHD-909, is a first-in-class oral SMARCA2 selective inhibitor currently in Phase 1 clinical trials for patients with SMARCA4-mutated cancers, with non-small cell lung cancer as the primary patient population. FHD-909 is being developed through a strategic collaboration with Eli Lilly and Company initiated in December 2021.
The company employs a biology-first approach, focusing on underlying genetics and disease-relevant targets before selecting the most appropriate drugging mechanism, which may include protein degraders, allosteric enzymatic inhibitors, or transcription factor disruptors. Foghorn's current pipeline addresses more than twenty tumor types impacting more than five hundred thousand cancer patients annually. The company believes it has potential to file four Investigational New Drug Applications over the next two years.
As of December 31, 2025, Foghorn had assembled a team of 106 employees with deep expertise in scientific research, clinical development, manufacturing, and biotechnology leadership.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1822462
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Foghorn Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Foghorn Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Foghorn Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Foghorn Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Foghorn Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”